First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.

21 The visual impairment and corneal morphology changes found on the ophthalmologic examination either fully recovered within 2-9 weeks or showed a trend toward resolution at the last follow-up assessment.

also in 53,322 other papers

All drug-related TEAEs either were reversible and resolved within 2-4 weeks of study drug cessation or showed a clear trend toward recovery at the last follow-up assessment.

also in 19,460 other papers

These findings suggest that, although there is a positive trend in the correlation between mesothelin expression and antitumor activity, significance cannot be established on the basis of the preliminary data from this study.

also in 11,005 other papers